Why Emergent Biosolutions Inc’s (EBS) Stock Is Up 5.31%

By Cynthia McLaughlin
May 17, 2024
Featured Tickers:
EBS

Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Emergent Biosolutions Inc before investing.

In this article, we go over a few key elements for understanding Emergent Biosolutions Inc’s stock price such as:

  • Emergent Biosolutions Inc’s current stock price and volume
  • Why Emergent Biosolutions Inc’s stock price changed recently
  • Upgrades and downgrades for EBS from analysts
  • EBS’s stock price momentum as measured by its relative strength

About Emergent Biosolutions Inc (EBS)

Before we jump into Emergent Biosolutions Inc’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a Bioservices portfolio. Its segments include Commercial Products, MCM Products, and Services Segment. Commercial Products segment include NARCAN (naloxone HCl). MCM Products segment consists of its Anthrax - MCM, Smallpox - MCM and Other Products. Services segment consisting of its Bioservices offerings. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression. Its portfolio of Bioservices consists of three but interrelated service pillars, such as development services (process and analytical development) and drug substance manufacturing.

Want to learn more about Emergent Biosolutions Inc’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Emergent Biosolutions Inc.

Learn More About A+ Investor

Emergent Biosolutions Inc’s Stock Price as of Market Close

As of May 17, 2024, 4:00 PM, CST, Emergent Biosolutions Inc’s stock price was $5.55.

Emergent Biosolutions Inc is up 5.31% from its previous closing price of $5.27.

During the last market session, Emergent Biosolutions Inc’s stock traded between $5.27 and $5.84. Currently, there are 52.20 million shares of Emergent Biosolutions Inc stock available for purchase.

Unfortunately, Emergent Biosolutions Inc’s P/E ratio is not significant enough to use for stock price evaluation. We recommend investors evaluate other financial metrics to understand its overall valuation.

Emergent Biosolutions Inc Stock Price History

Emergent Biosolutions Inc’s (EBS) price is currently up 195.21% so far this month.

During the month of May, Emergent Biosolutions Inc’s stock price has reached a high of $5.88 and a low of $1.87.

Over the last year, Emergent Biosolutions Inc has hit prices as high as $9.96 and as low as $1.42. Year to date, Emergent Biosolutions Inc’s stock is down 53.01%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Emergent Biosolutions Inc Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of May 16, 2024, there was 1 analyst who downgraded Emergent Biosolutions Inc’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Emergent Biosolutions Inc’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Emergent Biosolutions Inc’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Emergent Biosolutions Inc’s current valuation based on AAII’s Value Grade is a A, which means it is considered to be Deep Value.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Emergent Biosolutions Inc (EBS) by visiting AAII Stock Evaluator.

Relative Price Strength of Emergent Biosolutions Inc

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of May 16, 2024, Emergent Biosolutions Inc has a weighted four-quarter relative price strength of 59.54%, which translates to a Momentum Score of 98 and is considered to be Very Strong.

Want to learn more about how Emergent Biosolutions Inc is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Emergent Biosolutions Inc Stock Price: Bottom Line

As of May 17, 2024, Emergent Biosolutions Inc’s stock price is $5.55, which is up 5.31% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Emergent Biosolutions Inc stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.

Learn More About A+ Investor

Find New Stock Opportunities With Included With AAII Platinum
High Relative Dividend
Yield Screen:
8.7% Compared to S&P 500
at only 6.9%

Since Inception. Data as of 12/31/2024.




Try AAII Platinum and get full access to
769.3% Stock Superstars Portfolio Total Return Since Inception
Compare to:
710.3% iShare DOW Jones
U.S. Index ETF (IYY)

SSR Group 3 O'Shaughnessy portfolio has a 411.2% gain since inception performance compared to IYY at only 119.1%% Performance as of 11/29/24.

Get your free copy of our special report analyzing the tech stocks most likely to outperform the market.

Download the FREE Report Here:

BECOME A MEMBER FOR ONLY $2

Get access to powerful investment discovery tools and a wealth of investment education to help you achieve your financial goals.